CFO transition
OS Therapies Incorporated CFO transition: Francis (Frank) Knuettel II to succeed Christopher P. Acevedo
OS Therapies Incorporated reported in a Form 8-K filed October 5, 2026 that Francis (Frank) Knuettel II will succeed Christopher P. Acevedo as Chief Financial Officer, effective September 29, 2026.
In the filing's words
Effective September 29, 2026, the Board of Directors of OS Therapies Incorporated (the “Company”) appointed Francis (Frank) Knuettel II to serve as Chief Financial Officer of the Company and Kerry Clem to serve as Chief Commercial Officer of the Company.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | OS Therapies Incorporated (OSTX) |
|---|---|
| Event | Transition |
| Incoming | Francis (Frank) Knuettel II |
| Outgoing | Christopher P. Acevedo |
| Title in the filing | Chief Financial Officer |
| Effective | September 29, 2026 |
| 8-K filed | October 5, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer, Pelthos Therapeutics Inc. |
| SEC CIK | 0001795091 |
OS Therapies Incorporated reported this change in a Form 8-K, Item 5.02, filed October 5, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-10-06
Something wrong about Francis (Frank) Knuettel II? Send a correction with the primary source.